What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Gene
Maureen F. Zakowski focuses on Cancer research, Adenocarcinoma, Gefitinib, Erlotinib and Lung cancer.
Her studies deal with areas such as Mutation, KRAS, CDKN2A and Epidermal growth factor receptor as well as Cancer research.
As part of one scientific family, Maureen F. Zakowski deals mainly with the area of KRAS, narrowing it down to issues related to the Oncology, and often Lung.
Her Adenocarcinoma research entails a greater understanding of Cancer.
Her research in Erlotinib intersects with topics in T790M and Tyrosine-kinase inhibitor.
She interconnects Carcinoma and Gene expression profiling in the investigation of issues within Lung cancer.
Her most cited work include:
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib (3644 citations)
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2867 citations)
- Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network (2762 citations)
What are the main themes of her work throughout her whole career to date?
Maureen F. Zakowski mainly focuses on Pathology, Adenocarcinoma, Internal medicine, Oncology and Cancer research.
Her Adenocarcinoma study combines topics in areas such as KRAS, Lung cancer, Lung and Exon.
Her biological study spans a wide range of topics, including Gastroenterology and Endocrinology.
Maureen F. Zakowski studied Oncology and Stage that intersect with Proportional hazards model.
Her Cancer research research focuses on Erlotinib and how it relates to T790M and Tyrosine-kinase inhibitor.
Her Epidermal growth factor receptor study combines topics from a wide range of disciplines, such as Adenocarcinoma of the lung and Survival analysis.
She most often published in these fields:
- Pathology (33.15%)
- Adenocarcinoma (34.25%)
- Internal medicine (30.39%)
What were the highlights of her more recent work (between 2011-2018)?
- Adenocarcinoma (34.25%)
- Internal medicine (30.39%)
- Oncology (26.52%)
In recent papers she was focusing on the following fields of study:
Her primary scientific interests are in Adenocarcinoma, Internal medicine, Oncology, KRAS and Lung cancer.
Her Adenocarcinoma research incorporates elements of Radiology, Cytology, Lung and Exon.
Her study in Oncology is interdisciplinary in nature, drawing from both Chemotherapy, Epidermal growth factor receptor and Pathology.
The concepts of her KRAS study are interwoven with issues in Anaplastic lymphoma kinase, Cancer research and Erlotinib.
She has researched Erlotinib in several fields, including Survival rate and Gefitinib.
Her Lung cancer study integrates concerns from other disciplines, such as Carcinoma, Immunology, Lymph node and Gene expression profiling.
Between 2011 and 2018, her most popular works were:
- Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network (2762 citations)
- Comprehensive genomic characterization of squamous cell lung cancers (2590 citations)
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers (1387 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Her scientific interests lie mostly in Adenocarcinoma, KRAS, Cancer research, Pathology and Oncology.
Her research integrates issues of Lung cancer and Exon in her study of Adenocarcinoma.
She has included themes like Anaplastic lymphoma kinase, Erlotinib and Molecular biology in her KRAS study.
Her work deals with themes such as T790M and Gefitinib, which intersect with Erlotinib.
Her Pathology research incorporates themes from Micropapillary pattern and Pulmonary adenocarcinoma.
Maureen F. Zakowski combines subjects such as Internal medicine, Lung and Drug resistance with her study of Oncology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
